引用次数
引用: 28,310
H-指数: 49
I10-指数 : 90
出版物: 231
NCIC Pr 13 (Radicals) - An intergroup randomized controlled trial in prostate cancer of optimal timing of radiotherapy and duration of hormone therapy after radical prostatectomy (MRC PR10, ISRCTN40814031)
C Morash , M Sydes , C Catton , H Kynaston
Presented at: Joint Annual Meeting of the Canadian-Association-of-Radiation-Oncology/Canadian-Organization-of-Medical-Physicists (CARO-COMP 2007), Toronto, CANADA. (2007)
2
2007
Disease free survival (DFS) as a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP) - Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Working Group
C Sweeney , W Xie , M Regan , M Nakabayashi
Presented at: 2016 ASCO Annual Meeting, Poster Discussion Session: Genitourinary (Prostate) Cancer, Chicago, Illinois, USA. (2016)
2016
Abstract P4-14-03: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer
J-L Ethier , W Parulekar , L Shepherd , L Summers
Cancer Research 79
2
2019
P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis.
B Dong , J-AW Chapman , R Yerushalmi , PE Goss
Cancer Research 71
2011
Scoring oral mucositis
W Parulekar , R Mackenzie , G Bjarnason , R.C.K Jordan
Oral Oncology 34 ( 1) 63 -71
130
1998
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
W Xie , P Ravi , M Buyse , S Halabi
Annals of Oncology 35 ( 3) 285 -292
2
2024
DOES EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR (EGFRI) SKIN TOXICITY AFFECT QOL? RESULTS FROM A NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP (NCIC-CTG) RCT
HJ Au , D Goldstein , K Ding , W Parulekar
Quality of Life Research 14 ( 9) 2135 -2135
3
2005
Erlotinib improves clinical outcomes when added to gemcitabine in pancreatic cancer; prolonged survival among patients with metastatic disease. An exploratory sub-analysis of the NCIC. CTG study PA. 3
M Moore , K Ding , W Parulekar , J Kotecha
ANNALS OF ONCOLOGY 18 VII14 -VII14
2007
A catalogue of reporting guidelines for health research
Krleža-Jerić K PC , A Hróbjartsson , H Mann , K Dickersin
BMC Medicine 8 ( 18) 20334633 -20334633
1
2010
ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis , AJ Martin , MR Stockler , S Begbie
N Engl J Med 381 ( 2) 121 -131
115
2019
Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Samir S Taneja ,
JOURNAL OF UROLOGY 206 ( 6) 1519 -1520
2021
1.1 G Stereotactic Ablative Radiotherapy, September 16, 2021, 10: 30 AM–12: 30 PM
S Siva , W Parulekar , S Myrehaug , G Masucci
Journal of Medical Imaging and Radiation Oncology 65 ( S1) 242 -269
2021
Calibration Procedures for Multi-Center Dosimetry Studies with Lu-177 Radiopharmaceuticals: Early Experience from the Canadian Cancer Trial Group PR. 21 Trial (NCT 04663997)
C Uribe , N Colpo , J Brosch-Lenz , C Dellar
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 49 ( SUPPL 1) S186 -S187
2022
ORIGINAL REPORTS-Genitourinary Cancer-Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With
DS Ernst , IF Tannock , EW Winquist , PM Venner
Journal of Clinical Oncology 21 ( 17) 3335 -3342
2003
Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from RADICALS RT randomised controlled trial [NCT00541047]
C Parker , NW Clarke , A Cook , H Kynaston
European Urology Supplements 18 ( 11) e3618 -e3619
2019
INTERGROUP RANDOMIZED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY (ADT)+/-RADIATION THERAPY (RT) IN LOCALLY ADVANCED PROSTATE CANCER (CaP)(NCIC-CTG, SWOG, MRC-UK, INT: 94-0110, NCT 00002633)
P Warde , M Mason , M Sydes , G Swanson
RADIOTHERAPY AND ONCOLOGY 96 S16 -S16
1
2010
National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore , D Goldstein , J Hamm , A Figer
J Clin Oncol 25 ( 15) 1960 -1966
205
2007
Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]
MJ Moore , D Goldstein , J Hamm , J Kotecha
Proc Am Soc Clin Oncol 23 1a -1a
104
2005
Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment
A Altwairgi , A Alfakeeh , W Hopman , W Parulekar
EUROPEAN JOURNAL OF CANCER 49 S193 -S193
2013